John and Rashid’s believe that their OECT detection platform will revolutionize point-of-care diagnostics and impact the lives of millions of people worldwide.
ABOUT THE CO-FOUNDERS
John Murphy, BA
John is a graduate of the University of Alberta. Soon after graduation, he and one other guy started a software company called Shana, which they grew to about 100 employees, with offices throughout North America before executing a deliberately successful exit.
John went on to build another technology company based on molecular detection of high risk food pathogens. Ultimately the technology did not work – an unfortunate result, but it was a great learning experience and led to a US patent for a specialized prism. That innovation was the foundation for his next venture, Stream Technologies Inc. He engineered the prism into a novel multispectral camera paired with artificial intelligence to build a deep learning analytics platform.
When the pandemic hit, he thought that there had to be a way to use spectral imaging and artificial intelligence to make an ultra-rapid detection test for the SARS-CoV-2 virus. John connected with Rashid who was using mass spectrometry to look for cancer bio-markers. They pooled their talent and started Bio-Stream Diagnostics Inc. In 2021, Bio-Stream had the chance to acquire the IP for a new testing technology based on a novel organic electro chemical transistor (OECT). Right away, they recognized that this was a platform technology that was way bigger than just a COVID test.
This technology detects the electrical activity generated when an antibody and it’s target antigen bind. The antibodies are like corresponding ‘keys’ to the antigen protein’s ‘lock’. When the lock and key connect, it produces an electrical signal that is instantly measured as voltage by a reader. Change the antibody and you have a new test for another target of interest. There are thousands of potential antibody/antigen combinations that can be functionalized onto the same OECT hardware configuration. This technology is fast affordable, accurate and digitally enabled. Highly accurate results are returned in minutes and every test result can be captured and stored opening other exciting business opportunities.
Rashid Bux, MBA
Rashid received an undergraduate degree from Miami University and an MBA from the University of Western Ontario. Through out his career he has founded several different companies, which include his most recent endeavors; BioMark Diagnostics and BioMark Technologies started in 2006 to develop disruptive liquid biopsy cancer diagnostics solutions using metabolomics, radiomics machine learning and advanced liquid chromatography–mass spectrometry (LC–MS). His ambition is to detect and treat cancers such as lung, breast and GBM cancers.
Rashid is currently President, Chief Executive Officer & Director at BioMark Technologies Inc, President, Chief Executive Officer & Director at BioMark Diagnostics Inc. (founded in 2014), and Acting President at Bio-Stream (co-founded in 2020) .
He previously was President of Arhaus LLC, President at Homeworks Inc, Chief Operating Officer of Optima Health Solutions International Corp., and Chief Operating Officer for KKT Orthopedic Spine Center. These companies were all founded by Rashid.